Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06392854 · ClinicalTrials.gov registry record · Early Phase 1

Regional Lipolysis Insulin Regulation

A Early Phase 1 study of Obesity, sponsored by Mayo Clinic.

Recruiting
Registry status
Early Phase 1
Development phase
48
Enrollment target
1
Study location

NCT06392854: Recruiting Early Phase 1 study of Obesity, sponsored by Mayo Clinic.

NCT06392854 is a Early Phase 1 study of Obesity that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 48 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06392854, a Early Phase 1 study of Obesity, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Early Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

Adults who gain most of their excess weight in the abdominal area typically do not respond to insulin in the same way as lean adults. Researchers are trying to understand why fat tissue responds differently in people with different body types.

Conditions Studied

Interventions

  • DRUG Insulin

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2024-05-01
Est. Completion 2028-06
Phase Early Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06392854

The ClinicalTrials.gov registry entry for NCT06392854 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Insulin is the first listed.

NCT06392854 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06392854 about?

NCT06392854 is a clinical study titled "Regional Lipolysis Insulin Regulation". Adults who gain most of their excess weight in the abdominal area typically do not respond to insulin in the same way as lean adults. Researchers are trying to understand why fat tissue responds differently in people with different body types.

What is the current status of trial NCT06392854?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2024-05-01. Estimated completion is 2028-06.

What conditions does trial NCT06392854 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06392854?

The interventions under investigation include: Insulin (DRUG).

Who is sponsoring clinical trial NCT06392854?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06392854 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.